Noxopharm Ltd
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug… Read more
Noxopharm Ltd - Asset Resilience Ratio
Noxopharm Ltd (NOX) has an Asset Resilience Ratio of 33.92% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Noxopharm Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Noxopharm Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$1.55 Million | 33.92% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$1.55 Million | 33.92% |
Asset Resilience Insights
- Very High Liquidity: Noxopharm Ltd maintains exceptional liquid asset reserves at 33.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Noxopharm Ltd Industry Peers by Asset Resilience Ratio
Compare Noxopharm Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Noxopharm Ltd (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Noxopharm Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 0.00% | AU$0.00 | AU$10.13 Million | -- |
| 2022-06-30 | 30.08% | AU$8.00 Million | AU$26.59 Million | +9.19pp |
| 2021-06-30 | 20.90% | AU$10.00 Million | AU$47.85 Million | -46.76pp |
| 2019-06-30 | 67.66% | AU$2.91 Million | AU$4.30 Million | -19.04pp |
| 2018-06-30 | 86.69% | AU$12.61 Million | AU$14.55 Million | -0.20pp |
| 2017-06-30 | 86.89% | AU$2.46 Million | AU$2.83 Million | +86.74pp |
| 2016-06-30 | 0.15% | AU$9.56K | AU$6.21 Million | -- |